Table 4.
Patients with known RAS testing.
| Patient | Primary therapy | RAS testing | Secondary therapy | SVR |
|---|---|---|---|---|
| 1 | OBV/PTV/r+DSV+RBV 12 weeks |
not detected | LDV/SOF+RBV 12 weeks |
NO |
|
| ||||
| 5 | OBV/PTV/r+DSV 4 weeks |
not detected | LDV/SOF 12 weeks |
YES |
|
| ||||
| 7 | OBV/PTV/r+DSV 1 week |
not detected | LDV/SOF 12 weeks |
YES |
|
| ||||
| 15 | SOF+RBV 24 weeks |
not detected | SOF+DCV 12 weeks →SOF+RBV 12 weeks | YES |
|
| ||||
| 20 | LDV/SOF 8 weeks |
not detected | GZR/EBR+RBV 16 weeks |
YES |
|
| ||||
| 23 | ASV+DCV 24 weeks |
NS5A: L31V, Y93H NS3: S122R, D168E |
OBV/PTV/r+DSV+RBV 12 weeks |
NO |
|
| ||||
| 25 | ASV+DCV 24 weeks |
NS5A - Y93Y/H | LDV/SOF+RBV 24 weeks |
YES |
|
| ||||
| 28 | OBV/PTV/r+DSV+RBV 4 weeks |
not detected | LDV/SOF 24 weeks |
YES |
|
| ||||
| 29 | OBV/PTV/r+DSV+RBV 12 weeks |
not detected | LDV/SOF 24 weeks |
YES |
|
| ||||
| 30 | OBV/PTV/r+DSV+RBV 12 weeks |
NS3-170I | LDV/SOF 24 weeks |
YES |
|
| ||||
| 31 | ASV+DCV 24 weeks |
NS5A: 31V, 93H | OBV/PTV/r+DSV+RBV 12 weeks |
YES |
RAS: resistance associated substitution; OBV: ombitasvir; PTV: paritaprevir; DSV: dasabuvir; RBV: ribavirin; LDV: ledipasvir; SOF: sofosbuvir; ASV: asunaprevir; DCV: daclatasvir.